Alpha-Lipoic Acid: What It Is, What the Evidence Says, and Why Germany Got There First

Understanding IV Therapy

Alpha-lipoic acid does not get the same attention as Vitamin C or glutathione in wellness conversations, which is worth addressing because the evidence for it is arguably stronger and more specific than that for either of those in certain clinical contexts.

Here is a straightforward look at what ALA actually is, what the research supports, and why a compound approved as a prescription medication in Germany in 1959 is still classified as a dietary supplement in Canada.

What Alpha-Lipoic Acid Actually Is

Alpha-lipoic acid is a naturally occurring compound synthesized in the mitochondria and found in small amounts in both animal and plant tissues. It functions as a coenzyme in energy metabolism and is one of the few antioxidants that operates in both water-soluble and fat-soluble environments, which means it can reach cellular compartments that most antioxidants cannot access (Superti & Russo, 2024).

It is sometimes called the antioxidant of antioxidants because it directly regenerates other antioxidants, including glutathione, Vitamin C, and Vitamin E, after they have been oxidized. That regenerative capacity makes it functionally distinct from most antioxidant compounds (Superti & Russo, 2024).

Your body produces some ALA on its own, but not in quantities sufficient for therapeutic purposes. Dietary sources exist but contribute minimally. Supplementation, whether oral or intravenous, is the only way to achieve clinically meaningful concentrations.

The German Approval and What It Means

Alpha-lipoic acid has been approved in Germany as a prescription medication for the treatment of diabetic peripheral neuropathy and alcoholic neuropathy since 1959, and for liver disease for a similar period (University of Wisconsin Integrative Medicine, n.d.). In Germany, it is dispensed under brand names such as Thiogamma and Alpha-Lipogamma, covered by health insurance, and administered intravenously in clinical settings as part of standard treatment protocols (Liv Hospital, 2026).

Germany has one of the most rigorous pharmaceutical regulatory frameworks in the world. The approval of ALA as a prescription drug reflects decades of accumulated clinical evidence that regulators considered sufficient to support therapeutic use.

The evidence behind that approval is substantial. A meta-analysis of four randomized controlled trials involving 1,258 patients found that treatment with ALA at 600mg per day intravenously over three weeks was safe and significantly improved both positive neuropathic symptoms and neuropathic deficits to a clinically meaningful degree in diabetic patients with symptomatic polyneuropathy (Ziegler et al., 2004). A separate meta-analysis confirmed the robustness of these findings, with intravenous administration showing a pooled standardized mean difference of -2.81 in favour of ALA compared with placebo, representing a clinically meaningful reduction in neuropathy symptoms (Mijnhout et al., 2012).

The American Academy of Family Physicians summarised the evidence clearly: intravenous ALA can improve neuropathy symptoms when administered for three weeks, with a strength of recommendation based on two meta-analyses of randomized controlled trials (AAFP, 2016).

Why Canada Has Not Followed

In Canada, ALA is classified as a natural health product and dietary supplement rather than a prescription drug. Health Canada assessed ALA for use as a supplemental ingredient in foods and determined that the data were insufficient to establish acceptable conditions of use, and declined to permit its use as a supplemental food ingredient (Health Canada, n.d.).

This does not mean Health Canada considers ALA unsafe or ineffective. It means the regulatory pathway for natural health products in Canada operates differently from the pharmaceutical approval process in Germany, and that ALA has not been submitted through the drug approval pathway here, as it has in Europe.

The practical consequence is that IV ALA in Canada exists in the integrative and functional medicine space rather than the conventional medical one. Canadian physicians are generally familiar with the evidence, particularly in the context of diabetic neuropathy, but it is not a first-line treatment recommendation in Canadian clinical guidelines, the way it is in Germany.

This is a pattern worth recognizing. It reflects the broader dynamic discussed in our post on integrative medicine going mainstream: the regulatory and funding structures that determine which treatments become part of the standard of care are not purely driven by evidence. They are also shaped by pharmaceutical economics, submission processes, and institutional inertia. ALA cannot be patented. It has no commercial sponsor funding the regulatory submission process in Canada. The evidence exists. The pathway to standard-of-care status has simply not been pursued here in the same way.

What the Evidence Supports Beyond Neuropathy

Evidence for neuropathy treatment is the most robust, but ALA's antioxidant properties have been studied across a broader range of applications.

A 2025 ScienceDirect review examining 48 clinical and preclinical studies published between 1998 and 2024 found that injectable ALA demonstrated superior bioavailability and efficacy compared to oral forms in specific experimental settings, with findings highlighting benefits across metabolic, neurodegenerative, musculoskeletal, and gestational conditions, as well as oxidative damage prevention (ScienceDirect, 2025).

Research has also examined ALA's potential role in chemotherapy-induced peripheral neuropathy. A ScienceDirect review found that ALA exerts neuroprotective effects against chemotherapy-induced neurotoxicity in sensory neurons, protecting mitochondrial function and reducing oxidative damage, with the authors suggesting it may reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encouraging further confirmatory clinical trials (Melli et al., 2008).

A 2024 review in Antioxidants examined ALA's multifaceted role in cancer, noting that its mechanisms in cancer cells differ from those in normal cells, with pro-oxidative properties that represent an active area of ongoing research (Yan et al., 2024).

Important Clinical Considerations

ALA can lower blood glucose levels. Clients managing diabetes with insulin or oral medications should be aware of this before booking and discuss it with their GP or endocrinologist, as medication adjustments may be needed. This is part of our clinical screening process, and your nurse will review it before your session.

A full meal is required before an ALA infusion. Your nurse will complete a health assessment before treatment begins.

What Hyndford Hydration Offers

Our Vital Glow infusion delivers Alpha-Lipoic Acid intravenously, starting at $195. It is available for clients with neuropathy symptoms, those managing oxidative stress, clients incorporating ALA into a broader antioxidant protocol, or those recovering from chemotherapy-related nerve symptoms who are doing so in consultation with their oncology team.

IV delivery achieves plasma concentrations that oral supplementation cannot reliably match, which is specifically relevant for ALA, given that the strongest clinical evidence for neuropathy outcomes comes from intravenous rather than oral administration (AAFP, 2016).

IV therapy is supportive in nature. We do not diagnose or treat medical conditions, and we will not claim to. If you are managing diabetic neuropathy or a condition your GP is actively treating, please discuss IV ALA with your medical team before booking.

ALA infusions for clients managing neuropathy, whether diabetic or otherwise, require assessment by your physician and our Nurse Practitioner before proceeding. This is not a standard booking. Get in touch first, and we will work through the appropriate protocol with you and your medical team before any session is confirmed.

For clients booking Vital Glow for general antioxidant support rather than neuropathy management, standard clinical screening applies, and most clients proceed without additional steps.

All sessions are delivered to your door with no mandatory consultation fees for most clients. Clinical screening is completed before every visit under a valid BC medical directive. Travel is included within our Nanaimo service area. Outside Lantzville to Cedar? Get in touch for a travel quote.

Have a look at our Signature Infusions or get in touch with questions.

Ready? Reserve your infusion today.

References

American Academy of Family Physicians. (2016). Alpha-lipoic acid for treatment of diabetic peripheral neuropathy. American Family Physician, 93(9), 786.

Health Canada. (n.d.). Decision on alpha lipoic acid (ALA) as a supplemental ingredient in foods. https://www.canada.ca/en/health-canada/services/food-nutrition/supplemented-foods/list-permitted-food-ingredients/information-ingredients-foods/decision-alpha-lipoic-acid.html

Liv Hospital. (2026). Alpha-lipoic acid. https://int.livhospital.com/drugs/alpha-lipoic-acid/

McIlduff, C. E., & Rutkove, S. B. (2011). Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Therapeutics and Clinical Risk Management, 7, 377-385.

Melli, G., Taiana, M., Camozzi, F., Triolo, D., Podini, P., Quattrini, A., Taroni, F., & Lauria, G. (2008). Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Experimental Neurology, 214(2), 276-284.

Mijnhout, G. S., Kollen, B. J., Alkhalaf, A., Kleefstra, N., & Bilo, H. J. G. (2012). Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: A meta-analysis of randomized controlled trials. International Journal of Endocrinology. https://pmc.ncbi.nlm.nih.gov/articles/PMC3272801/

ScienceDirect. (2025). Therapeutic applications of alpha-lipoic acid: A review of clinical and preclinical evidence (1998-2024). https://www.sciencedirect.com/science/article/pii/S0753332225006742

Superti, F., & Russo, R. (2024). Alpha-lipoic acid: Biological mechanisms and health benefits. Antioxidants, 13(10), 1228. https://doi.org/10.3390/antiox13101228

University of Wisconsin Integrative Medicine. (n.d.). Supplement sampler: Alpha-lipoic acid. https://www.fammed.wisc.edu/files/webfm-uploads/documents/outreach/im/ss_alpha_lipoic_acid.pdf

Yan, S., Lu, J., Chen, B., Yuan, L., Chen, L., Ju, L., Cai, W., & Wu, J. (2024). The multifaceted role of alpha-lipoic acid in cancer prevention, occurrence, and treatment. Antioxidants, 13(8), 897. https://doi.org/10.3390/antiox13080897

Ziegler, D., Ametov, A., Barinov, A., Dyck, P. J., Gurieva, I., Low, P. A., Munzel, U., Yakhno, N., Raz, I., Novosadova, M., Maus, J., & Samigullin, R. (2006). Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. Diabetes Care, 29(11), 2365-2370.